NASDAQ$OPCH

Option Care Health, Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Option Care Health's financial performance increased due to revenue growth and strategic acquisitions.

Option Care Health reported a strong fourth quarter and full year in 2021, marked by a 15.2% increase in net revenue for Q4, reaching $927.2 million, and a net income of $75.5 million. The company's adjusted EBITDA for Q4 grew by 28.3% to $86.8 million. Additionally, Option Care Health completed the acquisition of Wasatch Infusion LLC and announced a definitive agreement to acquire Specialty Pharmacy Nursing Network, Inc.

  • Net revenue increased by 15.2% to $927.2 million compared to Q4 2020.
  • Gross profit rose by 15.5% to $212.2 million, representing 22.9% of revenue.
  • Net income was reported at $75.5 million, or $0.42 earnings per share, including a one-time tax benefit.
  • Adjusted EBITDA grew by 28.3% to $86.8 million compared to the same period last year.

Headline financials

Total Revenue

$927M

Previous: $805M+15.2%
EPS (adj)

$0.25

Previous: $0.10+150.0%
Adjusted EBITDA

$86.8M

Previous: $67.7M+28.2%
Capital Expenditures

$13.9M

Previous: $14M-0.8%
Free Cash Flow

$51.4M

Previous: $11.7M+341.0%
Net Income

$75.5M

Previous: $17.8M+323.2%
Operating Income

$60.8M

Previous: $44.3M+37.0%
Gross Profit

$212M

Previous: $184M+15.5%
Cash & Equivalents

$119M

Previous: $99.3M+20.3%
Total Assets

$2.79B

Previous: $2.65B+5.4%
Stock-Based Comp

$3.33M

Previous: $332K+902.7%

Revenue & EPS history

Option Care Health · Revenue · Quarterly

$927M

Q4 2021+15.2%vs Q4 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Forward guidance

For the full year 2022, Option Care Health expects to deliver net revenue between $3.65 billion and $3.85 billion, adjusted EBITDA between $310 million and $330 million, and cash flow from operations of at least $230 million. This guidance does not include the impact of the SPNN acquisition.

Tailwinds

  • Net revenue of $3.65 billion to $3.85 billion is expected.
  • Adjusted EBITDA of $310 million to $330 million is anticipated.
  • Cash flow from operations is projected to be at least $230 million.
  • The company is focused on patient-centered care, serving over a quarter of a million patients in 2021.
  • Continued investments are being made to drive future growth.

Headwinds

  • Ongoing challenging environment.
  • The financial expectations do not include any impact from the acquisition of SPNN.
  • Potential variability of material reconciling items.
  • Changes in laws and regulations applicable to the business model.
  • Changes in market conditions and receptivity to services and offerings.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-1.9%

Avg return

Earnings day

-4.2%

Avg return

5 days after

-1.9%

Avg return

30 days after

50%

36 / 72 earnings

Positive

+27.4%

Q3 2015

Best reaction

-53.6%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-24.3%-20.7%-22.4%
Q4 2025-7.3%-10.1%-23.1%
Q3 2025-8.7%-5.7%+8.5%
Q1 2025-6.9%-0.1%-2.2%
Q4 2024+1.6%+4.1%+6.4%
Q3 2024-24.5%-26.3%-22.0%
Q2 2024-1.9%-5.3%+2.1%
Q1 2024-1.6%-2.6%-6.0%
Q4 2023-3.4%-1.8%-2.0%
Q3 2023-15.6%-18.4%-8.1%
Q2 2023+5.3%+4.0%+7.9%
Q1 2023-14.7%-12.6%-11.4%
Q4 2022+7.1%+6.3%+9.4%
Q3 2022-10.9%-13.3%-17.6%
Q2 2022+5.0%+4.8%-2.2%
Q1 2022+10.3%+7.4%+14.2%
Q4 2021+8.6%+10.8%+20.9%
Q3 2021-0.0%-2.1%-12.1%
Q2 2021-0.1%+8.3%+35.1%
Q1 2021-4.7%-8.8%+2.3%
Q4 2020+2.2%+1.9%-3.7%
Q3 2020+11.4%+11.7%+14.1%
Q2 2020+3.6%+1.7%-2.8%
Q1 2020+8.8%+6.6%+32.7%
Q4 2019-12.8%-16.1%-48.4%
Q3 2019-2.4%-5.9%-16.3%
Q2 2019-1.4%-5.2%+21.5%
Q1 2019-2.5%-1.5%-4.0%
Q4 2018-33.0%-38.7%-50.4%
Q3 2018+16.0%+12.8%+34.2%
Q2 2018-1.5%+2.5%+4.4%
Q1 2018-6.1%-0.4%+6.9%
Q4 2017+3.3%+0.0%+9.8%
Q3 2017-13.8%-18.8%+5.8%
Q2 2017+8.6%+21.8%+6.8%
Q1 2017+3.6%+1.8%+24.2%
Q4 2016-12.3%-10.6%-33.9%
Q3 2016-53.6%-47.9%-56.3%
Q2 2016+3.0%+2.6%+2.3%
Q1 2016+3.1%
Q4 2015+7.1%
Q3 2015+27.4%
Q2 2015-22.8%
Q1 2015-10.0%
Q4 2014-11.3%
Q3 2014+1.3%
Q2 2014-4.4%
Q1 2014+2.1%
Q4 2013+6.3%
Q2 1997+9.0%
Q3 2013-4.6%
Q2 2013-17.2%
Q1 2013-0.1%
Q4 2012-1.5%
Q3 2012+3.7%
Q2 2012+11.0%
Q1 2012+3.2%
Q4 2011-1.5%
Q3 2011-11.2%
Q2 2011+1.5%
Q4 2010+1.5%
Q1 2011-1.4%
Q3 2010+8.1%
Q2 2010-3.0%
Q1 2009+0.9%
Q1 2010+3.4%
Q2 2009+2.6%
Q4 2007+2.6%
Q4 2009+2.6%
Q3 2009+5.6%
Q3 2008+5.6%
Q4 2008+5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro